EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to alpha-lipoic acid and “protection of the nerve system” (ID 3157) and increase in insulin sensitivity (ID 3158) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Publication; Tetens, Inge

Link to article, DOI: 10.2903/j.efsa.2011.2202

Publication date: 2011

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
SCIENTIFIC OPINION

Scientific Opinion on the substantiation of health claims related to alpha-lipoic acid and “protection of the nerve system” (ID 3157) and increase in insulin sensitivity (ID 3158) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

European Food Safety Authority (EFSA), Parma, Italy

SUMMARY

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to alpha-lipoic acid and “protection of the nerve system” and increase in insulin sensitivity. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.

The food constituent that is the subject of the health claims is alpha-lipoic acid. The Panel considers that alpha-lipoic acid is sufficiently characterised.

“Protection of the nerve system”

The claimed effect is “protection of nerve system”. The target population is assumed to be the general population.

From the references provided, which reported on the treatment of neurological complications of diabetes (i.e. diabetic polyneuropathy), the Panel considers that the claim is related to the treatment of a disease and does not comply with the criteria laid down in Regulation (EC) No 1924/2006.

1 On request from the European Commission, Question No EFSA-Q-2008-3889, EFSA-Q-2008-3890, adopted on 08 April 2011.

2 Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Levik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhausser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu


The Panel notes that the clarifications provided by Member States mention lipid peroxidation. A claim on alpha-lipoic acid and protection of body lipids from oxidative damage has already been assessed with an unfavourable outcome. The references cited for the current claim did not provide any additional scientific data which could be used to substantiate the claim.

**Increase in insulin sensitivity**

The claimed effect is “glucose metabolism”. The target population is assumed to be the general population. From the references provided, the Panel assumes that the claimed effect refers to an increase in insulin sensitivity. The Panel considers that an increase in insulin sensitivity is a beneficial physiological effect.

No references were provided from which conclusions could be drawn for the scientific substantiation of the claim.

On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of alpha-lipoic acid and an increase in insulin sensitivity.

**KEY WORDS**

alpha-lipoic acid, nervous system, insulin sensitivity, health claims.
### TABLE OF CONTENTS

Summary ............................................................. 1  
Table of contents .................................................. 3  
Background as provided by the European Commission ........................................ 4  
Terms of reference as provided by the European Commission .................................. 4  
EFSA Disclaimer .................................................... 4  
Information as provided in the consolidated list .................................................... 5  
Assessment ........................................................... 5  
1. Characterisation of the food/constituent ........................................................... 5  
2. Relevance of the claimed effect to human health .................................................. 5  
   2.1. “Protection of the nerve system” (ID 3157) ...................................................... 5  
   2.2. Increase in insulin sensitivity (ID 3158) .......................................................... 6  
3. Scientific substantiation of the claimed effect ...................................................... 6  
   3.1. Increase in insulin sensitivity (ID 3158) .......................................................... 6  
Conclusions ........................................................... 6  
Documentation provided to EFSA ................................................................. 7  
References ............................................................. 7  
Appendices ............................................................ 8  
Glossary and Abbreviations ......................................................... 14
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION
See Appendix A

TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION
See Appendix A

EFSA DISCLAIMER
See Appendix B
INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST

The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006\(^4\) submitted by Member States contains main entry claims with corresponding conditions of use and literature for similar health claims. EFSA has screened all health claims contained in the original consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria established by the NDA Panel to identify claims for which EFSA considered sufficient information had been provided for evaluation and those for which more information or clarification was needed before evaluation could be carried out\(^5\). The clarifications which were received by EFSA through the screening process have been included in the consolidated list. This additional information will serve as clarification to the originally provided information. The information provided in the consolidated list for the health claims which are the subject of this opinion is tabulated in Appendix C.

ASSESSMENT

1. Characterisation of the food/constituent

The food constituent that is the subject of the health claims is alpha-lipoic acid.

alpha-Lipoic acid, also known as thioctic acid, is a non-essential sulphur-containing food constituent, present in foods, generally bound to protein (lipoyllysine), at very low concentrations (around 0.3 mg/100 g for the richest natural sources, i.e. spinach for vegetables and kidney for meat). The natural compound is the R enantiomer, while in food supplements generally the racemic form (R/S) is used. It exists in redox forms, the oxidised form with a ring containing a disulfide bond or a reduced form, in which the ring has been opened forming two thiol groups (dihydrolipoic acid). Alpha-lipoic acid is measurable in foods by established methods.

The Panel considers that the food constituent, alpha-lipoic acid, which is the subject of the health claims, is sufficiently characterised.

2. Relevance of the claimed effect to human health

2.1. “Protection of the nerve system” (ID 3157)

The claimed effect is “protection of nerve system”. The Panel assumes that the target population is the general population.

From the references provided, which reported on the treatment of neurological complications of diabetes (i.e. diabetic polyneuropathy), the Panel considers that the claim is related to the treatment of a disease, and does not comply with the criteria laid down in Regulation (EC) No 1924/2006.

The Panel notes that the clarifications provided by Member States mention lipid peroxidation. A claim on alpha-lipoic acid and protection of body lipids from oxidative damage has already been assessed with an unfavourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010). The references cited for the present claim did not provide any additional scientific data which could be used to substantiate the claim.


2.2. Increase in insulin sensitivity (ID 3158)

The claimed effect is “glucose metabolism”. The Panel assumes that the target population is the general population.

From the references provided, the Panel assumes that the claimed effect refers to an increase in insulin sensitivity.

The Panel considers that an increase in insulin sensitivity is a beneficial physiological effect.

3. Scientific substantiation of the claimed effect

3.1. Increase in insulin sensitivity (ID 3158)

The references provided to substantiate the claim included one narrative review on alpha-lipoic acid on various health outcomes, which did not provide any original data that could be used to substantiate the claim. The Panel considers that no conclusions can be drawn from this reference for the scientific substantiation of the claim.

One reference reported on a human intervention study which addressed the effects of alpha-lipoic acid administered intravenously on insulin-mediated glucose disposal in patients with type 2 diabetes (Jacob et al., 1995). The Panel notes that the intravenous route of administration is not relevant for human nutrition, and considers that no conclusions can be drawn from this study for the scientific substantiation of the claim.

Another reference (Kamenova, 2006) reported on an open-label, case-control study which assessed the effect of oral administration of alpha-lipoic acid on insulin sensitivity in patients with type 2 diabetes (n=12) treated with metformin tablets. The Panel notes that metformin is known to increase insulin sensitivity in type 2 diabetic subjects, and considers that the evidence provided does not establish that type 2 diabetic subjects under pharmacological treatment with metformin are representative of the target population for which the claim is intended. The Panel considers that no conclusions can be drawn from this study for the scientific substantiation of the claim.

Konrad et al. (1999) studied the effect of alpha-lipoic acid administered orally (600 mg, twice daily) for four weeks on blood insulin and glucose concentrations using an oral glucose tolerance test (OGTT) and a modified frequently sampled intravenous glucose tolerance test (FSIGTT) in lean (n=10) and obese (n=10) male patients with type 2 diabetes. The Panel notes that this study is an uncontrolled, open-label intervention, and considers that no conclusions can be drawn from this study for the scientific substantiation of the claim.

The Panel concludes that a cause and effect relationship has not been established between the consumption of alpha-lipoic acid and an increase in insulin sensitivity.

CONCLUSIONS

On the basis of the data presented, the Panel concludes that:

- The food constituent, alpha-lipoic acid, which is the subject of the health claim, is sufficiently characterised.

“Protection of nerve system” (ID 3157)

- The claimed effect is “protection of nerve system”. The target population is assumed to be the general population.
The claim is related to the treatment of a disease, and does not comply with the criteria laid down in Regulation (EC) No 1924/2006.

A claim on alpha-lipoic acid and protection of body lipids from oxidative damage has already been assessed with an unfavourable outcome. The references cited for the present claim did not provide any additional scientific data which could be used to substantiate the claim.

**Increase in insulin sensitivity (ID 3158)**

- The claimed effect is “glucose metabolism”. The target population is assumed to be the general population. From the references provided, it is assumed that the claimed effect refers to an increase in insulin sensitivity. An increase in insulin sensitivity is a beneficial physiological effect.
- A cause and effect relationship has not been established between the consumption of alpha-lipoic acid and an increase in insulin sensitivity.

**DOCUMENTATION PROVIDED TO EFSA**

Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-3889, EFSA-Q-2008-3890). The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.


**REFERENCES**

EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010. Scientific Opinion on the substantiation of health claims related to alpha lipoic acid and protection of body lipids from oxidative damage (ID 1434, 3134), maintenance of normal blood cholesterol concentrations (ID 3134), increased beta-oxidation of fatty acids (ID 3134), maintenance of normal blood glucose concentrations (ID 1435, 3162), and “regeneration of genes, regeneration of gene transcription and the influence to activity NF kappa B” (ID 3133) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010; 8(2):1474, 12 pp.


APPENDICES

APPENDIX A

BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

The Regulation 1924/2006 on nutrition and health claims made on foods (hereinafter "the Regulation") entered into force on 19th January 2007.

Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted health claims other than those referring to the reduction of disease risk and to children's development and health. This Community list shall be adopted through the Regulatory Committee procedure and following consultation of the European Food Safety Authority (EFSA).

Health claims are defined as "any claim that states, suggests or implies that a relationship exists between a food category, a food or one of its constituents and health".

In accordance with Article 13 (1) health claims other than those referring to the reduction of disease risk and to children's development and health are health claims describing or referring to:

   a) the role of a nutrient or other substance in growth, development and the functions of the body; or
   b) psychological and behavioural functions; or
   c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the sense of hunger or an increase in the sense of satiety or to the reduction of the available energy from the diet.

To be included in the Community list of permitted health claims, the claims shall be:

   (i) based on generally accepted scientific evidence; and
   (ii) well understood by the average consumer.

Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 January 2008 accompanied by the conditions applying to them and by references to the relevant scientific justification. These lists have been consolidated into the list which forms the basis for the EFSA consultation in accordance with Article 13 (3).

ISSUES THAT NEED TO BE CONSIDERED

IMPORTANCE AND PERTINENCE OF THE FOOD

Foods are commonly involved in many different functions of the body, and for one single food many health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for functions affected by a large number of dietary factors it should be considered whether a reference to a single food is scientifically pertinent.

---

6 OJ L12, 18/01/2007
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).
It should also be considered if the information on the characteristics of the food contains aspects pertinent to the beneficial effect.

**SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE**

Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims should be scientifically substantiated by taking into account the totality of the available scientific data, and by weighing the evidence, and shall demonstrate the extent to which:

(a) the claimed effect of the food is beneficial for human health,

(b) a cause and effect relationship is established between consumption of the food and the claimed effect in humans (such as: the strength, consistency, specificity, dose-response, and biological plausibility of the relationship),

(c) the quantity of the food and pattern of consumption required to obtain the claimed effect could reasonably be achieved as part of a balanced diet,

(d) the specific study group(s) in which the evidence was obtained is representative of the target population for which the claim is intended.

EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the application for authorisation of health claims consistent criteria for the potential sources of scientific data. Such sources may not be available for all health claims. Nevertheless it will be relevant and important that EFSA comments on the availability and quality of such data in order to allow the regulator to judge and make a risk management decision about the acceptability of health claims included in the submitted list.

The scientific evidence about the role of a food on a nutritional or physiological function is not enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified functions in the body in a way which is relevant to health. Although an appreciation of the beneficial effect in relation to the nutritional status of the European population may be of interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or physiological effect for that population should not, however, condition such considerations.

Different types of effects can be claimed. Claims referring to the maintenance of a function may be distinct from claims referring to the improvement of a function. EFSA may wish to comment whether such different claims comply with the criteria laid down in the Regulation.

**WORDING OF HEALTH CLAIMS**

Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. However, the wording of health claims should also be commented by EFSA in its opinion.

There is potentially a plethora of expressions that may be used to convey the relationship between the food and the function. This may be due to commercial practices, consumer perception and linguistic or cultural differences across the EU. Nevertheless, the wording used to make health claims should be truthful, clear, reliable and useful to the consumer in choosing a healthy diet.

In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or other substance in growth, development and the functions of the body". Therefore, the requirement to
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the body should be carefully considered.

The specificity of the wording is very important. Health claims such as "Substance X supports the function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the various functions of the joints is described or referred to contrary to the latter example which specifies this by using the word "flexibility".

The clarity of the wording is very important. The guiding principle should be that the description or reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or "helps".

In addition, for functions affected by a large number of dietary factors it should be considered whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the scientific evidence.

Similar alternative wordings as mentioned above are used for claims relating to different relationships between the various foods and health. It is not the intention of the regulator to adopt a detailed and rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is not required that EFSA comments on each individual wording for each claim unless the wording is strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and comment generally on such elements relating to wording to ensure the compliance with the criteria laid down in the Regulation.

In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average consumer should be recalled. In addition, such assessment should take into account the particular perspective and/or knowledge in the target group of the claim, if such is indicated or implied.

**TERMS OF REFERENCE**

**HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO CHILDREN’S DEVELOPMENT AND HEALTH**

EFSA should in particular consider, and provide advice on the following aspects:

- Whether adequate information is provided on the characteristics of the food pertinent to the beneficial effect.

- Whether the beneficial effect of the food on the function is substantiated by generally accepted scientific evidence by taking into account the totality of the available scientific data, and by weighing the evidence. In this context EFSA is invited to comment on the nature and quality of the totality of the evidence provided according to consistent criteria.

- The specific importance of the food for the claimed effect. For functions affected by a large number of dietary factors whether a reference to a single food is scientifically pertinent.

In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent to which:
- the claimed effect of the food in the identified function is beneficial.

- a cause and effect relationship has been established between consumption of the food and the claimed effect in humans and whether the magnitude of the effect is related to the quantity consumed.

- where appropriate, the effect on the function is significant in relation to the quantity of the food proposed to be consumed and if this quantity could reasonably be consumed as part of a balanced diet.

- the specific study group(s) in which the evidence was obtained is representative of the target population for which the claim is intended.

- the wordings used to express the claimed effect reflect the scientific evidence and complies with the criteria laid down in the Regulation.

When considering these elements EFSA should also provide advice, when appropriate:

- on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides for additional labelling requirements addressed to persons who should avoid using the food; and/or warnings for products that are likely to present a health risk if consumed to excess.
APPENDIX B

EFSA DISCLAIMER

The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing of the food/food constituent, a positive assessment of its safety, nor a decision on whether the food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.

It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of use as proposed in the Consolidated List may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006.
**APPENDIX C**

Table 1. Main entry health claims related to alpha-lipoic acid, including conditions of use from similar claims, as proposed in the Consolidated List.

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>3157</td>
<td>Alpha lipoic acid</td>
<td>Protection of nerve system</td>
<td>Alpha lipoic acid helps to protect the nervous system.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clarification provided</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alpha lipoic acid (LA) is a powerful inhibitor of iron-dependent lipid peroxidation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>and reactive oxygen species and thus helps to protect the nervous system</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Conditions of use</strong></td>
<td><strong>200 – 600 mg minimally for 3 weeks</strong></td>
</tr>
<tr>
<td>3158</td>
<td>Alpha lipoic acid</td>
<td>glucose metabolism</td>
<td>Alpha lipoic acid is suitable for diabetics, people with impaired glucose tolerance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clarification provided</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Contributes to glucose metabolism/improves blood glucose levels</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Conditions of use</strong></td>
<td><strong>200 – 600 mg minimally for 4 weeks</strong></td>
</tr>
</tbody>
</table>
GLOSSARY AND ABBREVIATIONS

OGTT      Oral glucose tolerance test
FSIGTT    Frequently sampled intravenous glucose tolerance test